News articles about Teva Pharmaceutical Industries Limited (NYSE:TEVA) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries Limited earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.6937918300353 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Teva Pharmaceutical Industries Limited (TEVA) Given a $17.00 Price Target at Cantor Fitzgerald (americanbankingnews.com)
- A Look At Kare Schultz, The New CEO In Charge Of Teva (feeds.benzinga.com)
- Why Teva Pharmaceutical Industries Ltd. (ADR) Is Soaring (fool.com)
- Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Soars on New CEO News (investorplace.com)
- Teva’s New CEO Is A Positive Catalyst (feeds.benzinga.com)
Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up 19.35% on Monday, hitting $18.50. 98,546,039 shares of the stock were exchanged. The firm’s market cap is $18.80 billion. The firm’s 50 day moving average price is $20.66 and its 200 day moving average price is $29.02. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $52.66.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.25 earnings per share. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be given a $0.085 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 1.84%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.
TEVA has been the subject of several research reports. TheStreet downgraded shares of Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a report on Friday, August 25th. ValuEngine downgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 target price for the company. in a report on Monday, May 22nd. Deutsche Bank AG reiterated a “buy” rating and issued a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Finally, Credit Suisse Group downgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $25.00 to $13.00 in a report on Wednesday, August 23rd. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries Limited presently has an average rating of “Hold” and a consensus price target of $32.94.
TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Receives News Sentiment Rating of 0.21” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://sportsperspectives.com/2017/09/11/teva-pharmaceutical-industries-limited-teva-receives-news-sentiment-rating-of-0-21.html.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.